Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Oncogene

• Publication date

  1999-03-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1202509PMID 10208417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site

  1998influential reference
• Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.

  1998cited by this paper
• Methylation of the BRCA1 gene in sporadic breast cancer.

  1997cited by this paper
• Complex Regulation of the BRCA1 Gene*

  1997influential reference
• Hypermethylation of the APC (adenomatous Polyposis Coli) gene promoter region in human colorectal carcinoma

  1997cited by this paper
• Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique.

  1997cited by this paper
• Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.

  1996cited by this paper
• Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.

  1996cited by this paper
• Mutations and Polymorphisms in the familial early‐onset breast cancer (BRCA1) gene

  1996cited by this paper
• Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.

  1996cited by this paper
• THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS

  1996cited by this paper
• Hypermethylation of calcitonin gene regulatory sequences in human breast cancer as revealed by genomic sequencing

  1996cited by this paper
• The role of DNA methylation in cancer genetic and epigenetics.

  1996cited by this paper
• Growth retardation and tumour inhibition by BRCA1

  1996cited by this paper
• The BRCA1 and 1A1.3B promoters are parallel elements of a genomic duplication at 17q21.

  1996cited by this paper
• Progress in Pathology

  1995cited by this paper
• 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

  1995cited by this paper
• A somatic BRCA1 mutation in an ovarian tumour

  1995cited by this paper
• Somatic mutations in the BRCA1 gene in sporadic ovarian tumours

  1995cited by this paper
• Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

  1995influential reference
• Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression.

  1995cited by this paper
• Distinct transcription start sites generate two forms of BRCA1 mRNA.

  1995cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.

  1994cited by this paper
• Spl elements protect a CpG island from de novo methylation

  1994cited by this paper
• Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

  1994cited by this paper
• Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma

  1994cited by this paper
• Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island.

  1994cited by this paper
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1994cited by this paper
• BRCA1 mutations in primary breast and ovarian carcinomas.

  1994cited by this paper
• Allelic loss in ovarian cancer

  1993cited by this paper
• Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors.

  1993cited by this paper
• Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted.

  1993cited by this paper
• Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene.

  1991cited by this paper
• Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines.

  1988cited by this paper
• A general method for isolation of high molecular weight DNA from eukaryotes.

  1976cited by this paper
• Progress in Pathology

  1950cited by this paper

• DNA repair pathways in ovarian cancer: Implications for therapy and resistance.

  2025cites this paper
• The deubiquitinating enzyme Cezanne stabilizes BRCA1 by counteracting APC/C and Ube2S-dependent Lys11-linked ubiquitination

  2025cites this paper
• Validation and Performance of Quantitative BRCA1 and RAD51C Promoter Hypermethylation Testing in Breast and Ovarian Cancers.

  2024cites this paper
• BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine

  2024cites this paper
• Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.

  2024cites this paper
• The molecular significance of BRCA1 promoter methylation in peripheral blood cells in women with breast cancer in West Algeria

  2024cites this paper
• Shedding light on DNA methylation and its clinical implications: the impact of long-read-based nanopore technology

  2024cites this paper
• BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer

  2024cites this paper
• Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells

  2024influential citation
• Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer

  2023cites this paper
• A transcription‐independent mechanism determines rapid periodic fluctuations of BRCA1 expression

  2023cites this paper
• The impact of an educational and information systems initiative on somatic BRCA testing rates in patients with high grade serous tubo-ovarian cancer in Western Australia

  2023cites this paper
• Evaluation of BRCA1 Gene Promoter Methylation Status in Sporadic Breast Cancer Patients in Southwest of Iran

  2023cites this paper
• In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone Receptors in BRCA1-Associated Breast Cancers

  2023cites this paper
• A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients.

  2022cites this paper
• Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival

  2022cites this paper
• Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets

  2022cites this paper
• BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer

  2021cites this paper
• DNA Methylation in Genes Associated with the Evolution of Ageing and Disease: A Critical Review.

  2021cites this paper
• Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer

  2021cites this paper
• PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway.

  2021cites this paper
• The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis

  2021cites this paper
• TITLE : BRCA 1 promoter methylation and clinical outcomes in ovarian cancer : an individual patient data meta-analysis

  2021cites this paper
• Targeted Therapeutic Strategies for Triple-Negative Breast Cancer

  2021cites this paper
• DNA Methylation in Solid Tumors: Functions and Methods of Detection

  2021cites this paper
• The Histological Subtypes of Breast Cancer Seen in a Tertiary Hospital in South-East, Nigeria

  2020cites this paper
• Mechanism and significance of chromosome damage repair by homologous recombination.

  2020cites this paper
• BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis.

  2020cites this paper
• Molecular Trajectory of BRCA1 and BRCA2 Mutations

  2020cites this paper
• Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.

  2020cites this paper
• A molecular basis for Estrogen Receptor- α deficiency in BRCA1-linked breast cancer

  2019cites this paper
• Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.

  2019cites this paper
• Modulation of the Epigenome (Methylome) to Improve Chemotherapeutic Efficacy

  2019cites this paper
• Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients

  2019cites this paper
• Targeting Chromatin Remodeling for Cancer Therapy

  2019cites this paper
• Comprehensive Proteomic Profiling–derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas

  2018cites this paper
• Targeting DNA repair: the genome as a potential biomarker

  2018cites this paper
• DNA damage repair in ovarian cancer: unlocking the heterogeneity

  2018cites this paper
• Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

  2018cites this paper
• Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer

  2018cites this paper
• Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

  2018cites this paper
• Decoding methylation patterns in ovarian cancer using publicly available Next-Gen sequencing data

  2018cites this paper
• Synergism between BRCA1 Mutation and Impaired Estrogen Signaling in Oxidative Stress Modulation Makes Estrogen Responsive Tissues (Breast) More Susceptible to Develop Cancer

  2018cites this paper
• Defining Driver DNA Methylation Changes in Human Cancer

  2018cites this paper
• The unique DEK oncoprotein in women's health: A potential novel biomarker.

  2018cites this paper
• Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis

  2018cites this paper
• Correlation between the expression of BRCA-1 and BAG-1 proteins in triple negative breast cancer and its sensitivity to platinum-based chemotherapy

  2017cites this paper
• BRCA1 promoter methylation in peripheral blood cells and predisposition to breast cancer

  2017cites this paper
• Molecular aspects of tumor development and treatment for small intestinal neuroendocrine tumors

  2017cites this paper
• Effect of TPA and HTLV-1 Tax on BRCA1 and ERE controlled genes expression

  2017cites this paper
• The Role of DNA Repair in the Onset and Therapy of Ovarian Cancer

  2017cites this paper
• Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients

  2017cites this paper
• Transactivation of the estrogen receptor promoter by BRCA1

  2017cites this paper
• Epigenetic regulation of DNA repair genes and implications for tumor therapy.

  2017cites this paper
• BRCA1 Promoter Hypermethylationas an Early Diagnostic Tool for Breast Cancer

  2017cites this paper
• Genetics and epigenetics in small intestinal neuroendocrine tumours

  2016cites this paper
• DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer.

  2016cites this paper
• Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.

  2016cites this paper
• Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.

  2016cites this paper
• DNA Methylation and microRNA patterns are in association with the expression of BRCA 1 in ovarian cancer

  2016cites this paper
• Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia.

  2016influential citation
• ID 4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA 1 function in basal-like breast cancer

  2016cites this paper
• The identification of novel strategies for the prevention and treatment of breast cancer in BRCA1-mutation carriers

  2016cites this paper
• Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.

  2016cites this paper
• SiRNA and epigenetic aberrations in ovarian cancer.

  2016cites this paper
• Do platinum salts fit all triple negative breast cancers?

  2016cites this paper
• Application of RNAi-induced gene expression profiles for prognostic prediction in breast cancer

  2016cites this paper
• ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer.

  2016cites this paper
• Folic acid supplementation in vitro induces cell type-specific changes in BRCA1 and BRCA 2 mRNA expression, but does not alter DNA methylation of their promoters or DNA repair.

  2015cites this paper
• Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour

  2015cites this paper
• Chapter 26 – Epigenetics of Cisplatin Resistance

  2015cites this paper
• Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies

  2015cites this paper
• Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer

  2015cites this paper
• Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk

  2015cites this paper
• DNA Methylation:: An Epigenetic Marker of Breast Cancer Influenced by Nutrients Acting as an Environmental Factor

  2015cites this paper
• Expression of shelterin and shelterin-associated genes in breast cancer cell lines

  2014cites this paper
• BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

  2014cites this paper
• The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.

  2014cites this paper
• HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.

  2014cites this paper
• Novel Approaches to Studying BRCA Variants of Unknown Clinical Significance

  2014cites this paper
• Prevalence of BRCA1 gene mutation in breast cancer patients in Guangxi, China.

  2014cites this paper
• BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different

  2014cites this paper
• METHOD Open Access

  2014cites this paper
• DEVELOPMENT OF A FUNCTIONAL ASSAY FOR DETERMINATION OF BRCA1 CARRIER STATUS

  2014cites this paper
• HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.

  2014cites this paper
• DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (Review)

  2014cites this paper
• DNA methylation and miRNAs regulation in hereditary breast cancer: epigenetic changes, players in transcriptional and post- transcriptional regulation in hereditary breast cancer.

  2014cites this paper
• Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer

  2014cites this paper
• Gastroenteropancreatic endocrine tumors.

  2014cites this paper
• Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

  2014cites this paper
• Epigenetic modifications in breast cancer and their role in personalized medicine.

  2013cites this paper
• Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery

  2013cites this paper
• Breast Cancer Invasion and Metastasis

  2013cites this paper
• Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.

  2013cites this paper
• 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

  2013cites this paper
• Methylation of BRCA1 Promoter Region Is Associated with Unfavorable Prognosis in Women with Early-Stage Breast Cancer

  2013cites this paper
• Prognostic significance of BRCA1 expression in gastric cancer

  2013cites this paper
• High SINE RNA Expression Correlates with Post-Transcriptional Downregulation of BRCA1

  2013cites this paper
• Neuroendocrine tumours: cracking the epigenetic code.

  2013cites this paper
• miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.

  2013cites this paper